DrugBiological
Rilotumumab clinical trials
Also written AMG 102.
- studies test it
- 13
- open now
- 0
- in phase 3
- 3
- first study started
- 2008
How studies write it
Studies that test it under each name
Studies by the year they started
13 studies that test it; most in 2008 (3)
| Year | Studies |
|---|---|
| 2008 | 3 |
| 2009 | 1 |
| 2010 | 3 |
| 2011 | 2 |
| 2012 | 2 |
| 2014 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 10
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 6
Amgen (5) · NantBioScience, Inc. (1) · UNICANCER (1) · Gynecologic Oncology Group (1) · Ahmad Tarhini (1) · Katy Peters (1) · NantCell, Inc. (1) · SWOG Cancer Research Network (1)
Often tested with
Tested in the same studies.
Panitumumab (2) · Ganitumab (2) · Erlotinib (1) · Bevacizumab (1) · Cisplatin (1) · Pemetrexed (1)
Studies
Open first, then newest update. How each study uses rilotumumab is read from its arms, and is right about nine times in ten.
Testing it · 13
- QUILT-2.013: First-Line Treatment for Extensive Stage Small Cell Lung CancerTerminatedPhase 1/2NantCell, Inc.NCT00791154Written as AMG 102
- Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)CompletedPhase 1/2NantBioScience, Inc.NCT00788957Written as Rilotumumab
- MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal AdenocarcinomaCompletedPhase 2UNICANCERNCT01443065Written as AMG102
- Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker MatchesTerminatedPhase 2/3SWOG Cancer Research NetworkNCT02926638Written as Rilotumumab
- Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerCompletedPhase 2Gynecologic Oncology GroupNCT01039207Written as Rilotumumab
- AMG 102 and Erlotinib for Advanced Non-Small Cell Lung CancerCompletedPhase 1/2Ahmad TarhiniNCT01233687Written as AMG 102 and erlotinib
- A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric CancerTerminatedPhase 3AmgenNCT02137343Written as Rilotumumab
- Phase 1/1b Study of Rilotumumab in Japanese Subjects With Advanced Solid Tumors or Advanced or Metastatic Gastric or GEJCompletedPhase 1AmgenNCT01791374Written as Rilotumumab
- First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) AdenocarcinomaTerminatedPhase 3AmgenNCT01697072Written as Rilotumumab
- AMG 102 and Avastin for Recurrent Malignant GliomaCompletedPhase 2Katy PetersNCT01113398Written as AMG 102
- AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate CancerCompletedPhase 1/2AmgenNCT00770848Written as AMG 102
- AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction CancerCompletedPhase 1/2AmgenNCT00719550Written as AMG 102
- AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural MesotheliomaWithdrawnPhase 2National Cancer Institute (NCI)NCT01105390Written as rilotumumab
Codes
What other systems call rilotumumab · ClinicalTrials.gg INT005183
- MeSH (NLM) C524459rilotumumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 51WEW898IJRILOTUMUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q7334301RilotumumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C67079RilotumumabOne source FDA
- DrugBank DB11972One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C524459 | rilotumumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 51WEW898IJ | RILOTUMUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q7334301 | Rilotumumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C67079 | Rilotumumab | One source FDA |
| DrugBank | DB11972 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.